Nuvalent to be acquired by GSK for $10.6B in all-cash tender offer at $124/share
NUVL sits 73% above its 52-week low of $71.13 on elevated volume (35× avg).
Summary
Nuvalent, Inc. announced a definitive merger agreement to be acquired by GlaxoSmithKline LLC for $10.6 billion in an all-cash tender offer of $124 per share, representing a 40% premium.
Key Events · M&A and Partnerships · NUVL
-
Acquisition by GSK
Nuvalent, Inc. has entered into a definitive merger agreement to be acquired by GlaxoSmithKline LLC for an aggregate equity value of approximately $10.6 billion.
-
All-Cash Tender Offer
GSK will acquire all outstanding shares of Nuvalent for $124 per share in an all-cash transaction. This price represents a 40% premium to Nuvalent's closing price on June 8, 2026.
-
Board Approval and Shareholder Support
The transaction was unanimously approved by Nuvalent's Board. Entities affiliated with Deerfield Partners LP and all directors and officers, representing approximately 28% of outstanding shares, have signed tender and support agreements.
-
Expected Closing
The transaction is expected to close in the third quarter of 2026, subject to customary regulatory approvals and the tender of a majority of Class A common stock.
Analysis · NUVL · Life Sciences
This filing confirms the definitive merger agreement for GSK to acquire Nuvalent for $10.6 billion in an all-cash tender offer. The offer price of $124 per share represents a substantial 40% premium over Nuvalent's closing price on June 8, 2026, and is near the company's 52-week high. This transaction fundamentally alters the investment thesis for Nuvalent shareholders, providing immediate and certain cash value at a significant premium, and effectively marks the end of Nuvalent as an independent publicly traded company. The unanimous board approval and tender support agreements from major shareholders (28% of shares) indicate a high probability of the deal closing in Q3 2026.
At the time of this filing, NUVL was trading at $123.35 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $9.7B. The 52-week trading range was $71.13 to $123.62. This filing was assessed with positive market sentiment and an importance score of 10 out of 10.